These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 19307693)
41. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall. Jia G; Aroor AR; Sowers JR Cardiovasc Res; 2017 Jul; 113(9):1055-1063. PubMed ID: 28838041 [TBL] [Abstract][Full Text] [Related]
47. Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease. Parker BM; Wertz SL; Pollard CM; Desimine VL; Maning J; McCrink KA; Lymperopoulos A Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486399 [TBL] [Abstract][Full Text] [Related]
48. The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease. Pantelidis P; Sideris M; Viigimaa M; Avranas K; Deligkaris P; Zografou I; Lovic D Curr Pharm Des; 2018; 24(46):5491-5499. PubMed ID: 30767735 [TBL] [Abstract][Full Text] [Related]
49. Targeting the aldosterone pathway in cardiovascular disease. Gustafsson F; Azizi M; Bauersachs J; Jaisser F; Rossignol P Fundam Clin Pharmacol; 2012 Feb; 26(1):135-45. PubMed ID: 22044496 [TBL] [Abstract][Full Text] [Related]
50. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Joffe HV; Adler GK Heart Fail Rev; 2005 Jan; 10(1):31-7. PubMed ID: 15947889 [TBL] [Abstract][Full Text] [Related]
51. Specific Activation of the Alternative Cardiac Promoter of Mesquita TR; Auguste G; Falcón D; Ruiz-Hurtado G; Salazar-Enciso R; Sabourin J; Lefebvre F; Viengchareun S; Kobeissy H; Lechène P; Nicolas V; Fernandez-Celis A; Gómez S; Lauton Santos S; Morel E; Rueda A; López-Andrés N; Gómez AM; Lombès M; Benitah JP Circ Res; 2018 Mar; 122(7):e49-e61. PubMed ID: 29467196 [TBL] [Abstract][Full Text] [Related]
52. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Adams KF Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833 [TBL] [Abstract][Full Text] [Related]
53. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Jaisser F; Farman N Pharmacol Rev; 2016 Jan; 68(1):49-75. PubMed ID: 26668301 [TBL] [Abstract][Full Text] [Related]
54. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631 [TBL] [Abstract][Full Text] [Related]
56. Identification and role of aldosterone receptors in the cardiovascular system. Lombès M; Farman N; Bonvalet JP; Zennaro MC Ann Endocrinol (Paris); 2000 Feb; 61(1):41-6. PubMed ID: 10790591 [TBL] [Abstract][Full Text] [Related]
57. Rationale for the use of aldosterone antagonists in congestive heart failure. Rocha R; Williams GH Drugs; 2002; 62(5):723-31. PubMed ID: 11929327 [TBL] [Abstract][Full Text] [Related]
58. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Lakkis J; Lu WX; Weir MR Curr Hypertens Rep; 2003 Oct; 5(5):408-17. PubMed ID: 12948434 [TBL] [Abstract][Full Text] [Related]
59. Endothelial Dysfunction in Primary Aldosteronism. Chen ZW; Tsai CH; Pan CT; Chou CH; Liao CW; Hung CS; Wu VC; Lin YH; Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640178 [TBL] [Abstract][Full Text] [Related]
60. Role of brain aldosterone and mineralocorticoid receptors in aldosterone-salt hypertension in rats. Wang HW; Huang BS; Chen A; Ahmad M; White RA; Leenen FH Neuroscience; 2016 Feb; 314():90-105. PubMed ID: 26656220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]